Jun 11, 2019 / 09:40PM GMT
Salveen Jaswal Richter - Goldman Sachs Group Inc., Research Division - VP
Good afternoon, everyone. I'm Salveen Richter, one of the biotechnology analysts at Goldman Sachs.
And we're pleased to have the Agios team here with us. So we have Jackie Fouse, CEO; and Andrew Hirsch, CFO.
Questions and Answers:
Salveen Jaswal Richter - Goldman Sachs Group Inc., Research Division - VPMaybe to start here, you could walk us through the long-term strategy for Agios. You've got 2 commercial drugs. You've got label expansions on TAP and a pretty broad research pipeline. So looking forward, how do you continue executing in a focused manner while you expand the pipeline here with these opportunities?
Jacqualyn A. Fouse - Agios Pharmaceuticals, Inc. - CEO & Director
Yes. Salveen, I guess the first thing I would say is you come into a terrific company, position of strength, you just don't want to mess it up, right? So I think that's one thing. But we're going to continue to -- the Agios' tradition of following the
Trustpilot
